›› 2010, Vol. 28 ›› Issue (3): 13-225.

• 综述 • Previous Articles     Next Articles

Progress in Development of New AntischistosomalDrugs in Recent Years

XIAO Shu-hua   

  1. National Institute of Parasitic Diseases，Chinese Center for Disease Control and Prevention；Key Laboratory of Parasite and Vector Biology，MOH；WHO collaborating Center for Malaria，Schistosomiasis and Filariasis，Shanghai 200025，China
  • Received:1900-01-01 Revised:1900-01-01 Online:2010-06-30 Published:2010-06-30

PDF (PC)

1024

Abstract: 【Abstract】 It is estimated that 200 million people have suffered the infection with schistosomes in the world. The fact that treatment of schistosomiasis only relies on a single drug praziquantel does not adapt to the demand. Although praziquantel exhibits excellent therapeutic efficacy， it shows no preventive action to the infection. Therefore， development of new anti-schistsomal drugs has been received serious attention. In this paper the recent development of new anti-schistosomal drugs such as oxadiazole-2-oxides， mefloquine， etc. has been reviewed， and the process of their development and anti-schistosomal properties recounted.

Key words: Schistosome, Schistosomiasis, Oxadizole-2-oxides, Mefloquine, Praziquantel